Mathematical Modelling of the Inhibitory Role of Regulatory T Cells in Tumor Immune Response
暂无分享,去创建一个
Yueping Dong | Yasuhiro Takeuchi | Zhongtao Yang | Cuihong Yang | Y. Takeuchi | Yueping Dong | Cuihong Yang | Zhongtao Yang
[1] C. Chen,et al. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer , 2016, Oncotarget.
[2] George Coukos,et al. T-regulatory cells: key players in tumor immune escape and angiogenesis. , 2012, Cancer research.
[3] A. d’Onofrio. A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences , 2005, 1309.3337.
[4] S. Quezada,et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. , 2006, Current opinion in immunology.
[5] Y. Lai,et al. The Roles of CD4+ T Cells in Tumor Immunity , 2011 .
[6] Doron Levy,et al. A Mathematical Model of the Enhancement of Tumor Vaccine Efficacy by Immunotherapy , 2012, Bulletin of mathematical biology.
[7] T. Mak,et al. Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.
[8] Loise M. Francisco,et al. The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.
[9] Yasuhiro Takeuchi,et al. Mathematical modeling on helper T cells in a tumor immune system , 2013 .
[10] J. Liu,et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor , 2017, Nature Immunology.
[11] Tongqian Zhang,et al. The stationary distribution of a microorganism flocculation model with stochastic perturbation , 2020, Appl. Math. Lett..
[12] Meng Liu,et al. Analysis of a stochastic tumor-immune model with regime switching and impulsive perturbations , 2020 .
[13] Gideon Blumenthal,et al. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy , 2016, The oncologist.
[14] B. Levine,et al. The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells , 2011, Science Translational Medicine.
[15] A. Albert,et al. Tumors and the immune system: the effects of a tumor growth modulator☆ , 1980 .
[16] Yan Yang,et al. Tumour chemotherapy strategy based on impulse control theory , 2017, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.
[17] D. Kirschner,et al. Modeling immunotherapy of the tumor – immune interaction , 1998, Journal of mathematical biology.
[18] N. Rashevsky. Suggestions for a mathematical biophysics of some psychoses. , 1947, The Bulletin of mathematical biophysics.
[19] Hiroyoshi Nishikawa,et al. Regulatory T cells: a potential target in cancer immunotherapy , 2018, Annals of the New York Academy of Sciences.
[20] R. Durrett,et al. Ordinary Differential Equation Models for Adoptive Immunotherapy , 2018, Bulletin of mathematical biology.
[21] Roberto Barbuti,et al. Tumour suppression by immune system through stochastic oscillations. , 2010, Journal of theoretical biology.
[22] Magda Galach,et al. DYNAMICS OF THE TUMOR—IMMUNE SYSTEM COMPETITION—THE EFFECT OF TIME DELAY , 2003 .
[23] Min Yu,et al. Dual role of delay effects in a tumour–immune system , 2017, Journal of biological dynamics.
[24] C. Voena,et al. Advances in cancer immunology and cancer immunotherapy. , 2016, Discovery medicine.
[25] Y. Takeuchi,et al. Mathematical modeling and bifurcation analysis of pro- and anti-tumor macrophages , 2020 .
[26] Gang Huang,et al. Dynamics in a tumor immune system with time delays , 2015, Appl. Math. Comput..
[27] Yasuhiro Takeuchi,et al. Complicated dynamics of tumor-immune system interaction model with distributed time delay , 2020 .
[28] Svetlana Bunimovich-Mendrazitsky,et al. Mathematical Model of Pulsed Immunotherapy for Superficial Bladder Cancer , 2008, Bulletin of mathematical biology.
[29] B. Foster,et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.
[30] M. Delitala,et al. How combination therapies shape drug resistance in heterogeneous tumoral populations , 2018 .
[31] O. Sotolongo-Costa,et al. Behavior of tumors under nonstationary therapy , 2002 .
[32] A. Radunskaya,et al. Mathematical Modeling of Tumor Immune Interactions: A Closer Look at the Role of a PD-L1 Inhibitor in Cancer Immunotherapy , 2018 .
[33] Michael S. Kuhns,et al. CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.
[34] L. Coussens,et al. Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.
[35] A. Radunskaya,et al. Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .
[36] Jason T. George,et al. Stochastic modeling of tumor progression and immune evasion. , 2018, Journal of theoretical biology.
[37] P. Bruggen,et al. Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.
[38] Helen M. Byrne,et al. A mathematical model of cytotoxic and helper T cell interactions in a tumour microenvironment , 2018 .
[39] Y. Horio. [Management of Toxicities of Immune Checkpoint Inhibitors]. , 2017, Gan to kagaku ryoho. Cancer & chemotherapy.
[40] Zhichao Jiang,et al. Global dynamics of a model for treating microorganisms in sewage by periodically adding microbial flocculants. , 2019, Mathematical biosciences and engineering : MBE.
[41] A. Perelson,et al. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.
[42] M Tubiana,et al. Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about? , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] Yuri A. Kuznetsov,et al. MATCONT: a Matlab package for numerical bifurcation analysis of ODEs , 2004, SIGS.
[44] Hermann B. Frieboes,et al. Mathematical modeling of tumor-immune cell interactions. , 2019, Journal of theoretical biology.
[45] G. Freeman,et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. , 2013, The Journal of clinical investigation.
[46] Xiaofeng Han,et al. Dynamics analysis of a delayed virus model with two different transmission methods and treatments , 2020, Advances in Difference Equations.